<DOC>
	<DOCNO>NCT00860938</DOCNO>
	<brief_summary>Study purpose evaluate subject chronic obstructive pulmonary disease ( COPD ) likely responsive additional inhaled corticosteroid positive response hyperosmolar challenge mannitol response negative .</brief_summary>
	<brief_title>Predictor Additional Benefit Inhaled Corticosteroid Patients Treated With Tiotropium COPD</brief_title>
	<detailed_description>In patient chronic obstructive pulmonary disease ( COPD ) , treatment inhaled corticosteroid ( ICS ) controversial . Preliminary result recent pilot study 30 COPD patient show first time , ICS response mey predict bronchoprovocation challenge test mannitol . However , find need proven placebo-controlled trial . For cohort study , 100 corticosteroid-naive , non reversible ( FEV1 ) patient COPD recruit . Spirometry bronchodilation measure study entry four week run-in ( tiotropium ) three month treatment tiotropium ICS placebo . Quality life ( St. George Respiratory Quality Life Questionnaire ) exacerbation rate COPD assess . Measurement exhale nitric oxide mannitol challenge perform study entry 1 4 month . Primary endpoint improvement FEV1 group ( positive negative mannitol challenge ) 3 month follow . Secondary endpoint difference dose-response-curve mannitol challenge , exacerbation rate change quality life three month follow-up .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>FEV1/FVC &lt; 70 % FEV1 % predict &gt; 60 % Other major disease Asthma Currently take inhaled corticosteroid oral corticosteroid last 3 month significant cardiovascular disease pregnancy/breast feed current use salmeterol long act bronchodilator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Inhaled corticosteroid</keyword>
	<keyword>COPD</keyword>
	<keyword>mannitol</keyword>
</DOC>